FilingReader Intelligence
Suven Life Sciences losses widen despite CNS pipeline progress
July 30, 2025 at 08:21 AM UTC•By FilingReader AI
Suven Life Sciences reported a net loss of C16,074 lakhs for FY25, up from C10,508 lakhs previously. Revenue from operations fell to C666 lakhs from C1,169 lakhs, while negative EBITDA doubled to C166 crore.
The company is advancing 13 CNS molecules, with 5 in clinical trials. Masupirdine is in Phase 3, while Samelisant is initiating Phase 3 trials.
Suven secured C857 crore through convertible warrants to fund R&D and clinical development.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:SUVEN•Bombay Stock Exchange
News Alerts
Get instant email alerts when Suven Life Sciences publishes news
Free account required • Unsubscribe anytime